Scholarlink

Background <p>Cardiovascular diseases remain a leading global health challenge, necessitating effective antiplatelet therapies to mitigate thrombotic risks. Conventional antiplatelet agents, such as acetylsalicylic acid (ASA) and purinergic receptor type Y, subtype 12 (P2Y12) inhibitors, are effective but present limitations, including bleeding complications and resistance in some patients. This study investigates the antiplatelet potential of polysaccharide fractions extracted from fruiting bodies of eight different edible <i>Pleurotus</i> mushroom species cultivated for the purpose of this research.</p> Methods <p>Mushroom polysaccharide fractions were extracted from eight <i>Pleurotus</i> species (<i>P</i>. <i>citrinopileatus</i>, <i>P</i>. <i>columbinus</i>, <i>P</i>. <i>djamor</i>, <i>P</i>. <i>eryngii</i>, <i>P</i>. <i>florida</i>, <i>P</i>. <i>ostreatus</i>, <i>P</i>. <i>pulmonarius</i>, and <i>P</i>. <i>sajor</i>-<i>caju</i>) with cold water. Using multiple electrode aggregometry, we evaluated their inhibitory effects on platelet aggregation induced by adenosine-5′-diphosphate (ADP) and arachidonic acid (AA).</p> Results <p>Polysaccharides from all tested <i>Pleurotus</i> species exhibit significant inhibition of ADP-induced platelet aggregation in the 69–75% range, comparable to or exceeding that of ASA. While their beneficial effect on AA-induced aggregation was lower and limited to selected species with inhibition in the 6–46% range, polysaccharides from <i>P</i>. <i>djamor</i> and <i>P. sajor-caju</i> demonstrated promising dual inhibition.</p> Conclusions <p>This study suggests that <i>Pleurotus</i>-derived polysaccharides may serve as potential natural alternatives or adjuncts to existing antiplatelet therapies. Further in vivo studies and clinical trials are warranted to investigate their therapeutic potential in the prevention and management of cardiovascular disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antiplatelet potencies of polysaccharides extracted from eight cultivated edible Pleurotus mushroom species

  • 期刊论文

  • 发表日期：

    2025年4月21日

查看全文
  • Barbara Poniedziałek,
  • Marek Siwulski,
  • Iwona Komaniecka,
  • Adrian Wiater,
  • Adam Choma,
  • Joanna Rosińska,
  • Barbara Frąszczak,
  • Piotr Rzymski

摘要

Background

Cardiovascular diseases remain a leading global health challenge, necessitating effective antiplatelet therapies to mitigate thrombotic risks. Conventional antiplatelet agents, such as acetylsalicylic acid (ASA) and purinergic receptor type Y, subtype 12 (P2Y12) inhibitors, are effective but present limitations, including bleeding complications and resistance in some patients. This study investigates the antiplatelet potential of polysaccharide fractions extracted from fruiting bodies of eight different edible Pleurotus mushroom species cultivated for the purpose of this research.

Methods

Mushroom polysaccharide fractions were extracted from eight Pleurotus species (P. citrinopileatus, P. columbinus, P. djamor, P. eryngii, P. florida, P. ostreatus, P. pulmonarius, and P. sajor-caju) with cold water. Using multiple electrode aggregometry, we evaluated their inhibitory effects on platelet aggregation induced by adenosine-5′-diphosphate (ADP) and arachidonic acid (AA).

Results

Polysaccharides from all tested Pleurotus species exhibit significant inhibition of ADP-induced platelet aggregation in the 69–75% range, comparable to or exceeding that of ASA. While their beneficial effect on AA-induced aggregation was lower and limited to selected species with inhibition in the 6–46% range, polysaccharides from P. djamor and P. sajor-caju demonstrated promising dual inhibition.

Conclusions

This study suggests that Pleurotus-derived polysaccharides may serve as potential natural alternatives or adjuncts to existing antiplatelet therapies. Further in vivo studies and clinical trials are warranted to investigate their therapeutic potential in the prevention and management of cardiovascular disease.